ライフサイエンスコーパス: indolent

1 se, as in most cases the disease will remain indolent.

2 ients with new compared with slow-growing or indolent (0.9% per year) cancer.

3 owing and 31 (25.8%) slow-growing (15.0%) or indolent (10.8%) cases.

4 ajor/partial R: 0%/47%/25%) and according to indolent/advanced M was 92% (major/partial R: 56%/36%) a

5 rating a universal definition for PJI due to indolent agents of infection, such as P. acnes.

6 A distinction between indolent and aggressive disease is a major challenge in

7 ide useful criteria to differentiate between indolent and aggressive FMF and confirm the existence of

8 Distinction between indolent and aggressive FMF may have important therapeut

9 ere identified as useful for differentiating indolent and aggressive forms of PCa.

10 across multiple lymphoma subtypes, including indolent and aggressive forms.

11 neoplastic mast cells and is classified into indolent and aggressive forms.

12 re 3.71 (0.1-8) and 2.47 (0.5-8.6) years for indolent and aggressive M, respectively.

13 Distinguishing between indolent and aggressive prostate adenocarcinoma remains

14 lines into established gene expression-based indolent and aggressive subtypes.

15 We have isolated two syngeneic cell lines (indolent and aggressive) through in vivo selection by im

16 1q-binding dnDSA could differentiate between indolent and harmful dnDSA causing antibody-mediated rej

17 s varied, with low-grade disease often being indolent and high-grade cancer accounting for the greate

18 GC) B cells leading to the development of an indolent and largely incurable disease.

19 liably informative biomarkers to distinguish indolent and lethal prostate cancer is one reason this d

20 Patients with relapsed or refractory indolent and mantle cell lymphoma with adequate organ fu

21 ab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and labor

22 and care, such as use of new terminology for indolent and precancerous disorders.

23 ic profiles of plasma exosomes, both between indolent and progressive CLLs as well as within the indi

24 d on needle biopsies are generally viewed as indolent and suitable for conservative management with o

25 ar ataxia type 28 disease--in a patient with indolent ataxia and PEO.

26 Among indolent B cell lymphoproliferative disorders, NOTCH2 mu

27 activity in chronic lymphocytic leukemia and indolent B cell non-Hodgkin's lymphomas.

28 timulatory domains in patients with relapsed indolent B-cell and mantle cell lymphomas.

29 Hairy cell leukemia (HCL) is a rare, indolent B-cell disorder in which single courses of clad

30 ed on a therapeutic vaccination strategy for indolent B-cell lymphoma that combines local radiation t

31 c leukemia (CLL) is typically regarded as an indolent B-cell malignancy.

32 Follicular lymphoma (FL) is an indolent B-cell non-Hodgkin lymphoma able to transform i

33 of dulanermin to rituximab in patients with indolent B-cell non-Hodgkin lymphoma was tolerable but d

34 Eight patients with relapsed CD37+ indolent B-cell non-Hodgkin lymphoma were included for R

35 In phase 1b, patients (age >/=18 years) with indolent B-cell non-Hodgkin lymphoma with stable disease

36 rmin and rituximab in patients with relapsed indolent B-cell non-Hodgkin lymphoma.

37 e disease response (LDR) of 46 patients with indolent B-cell non-Hodgkin lymphomas (NHLs) or chronic

38 dal marginal zone lymphoma (NMZL) is a rare, indolent B-cell tumor that is distinguished from splenic

39 For the aggressive B-cell, indolent B-cell, and T-cell and Hodgkin lymphoma (HL/T)

40 The frequency of cancers with indolent behavior has increased with screening.

41 also occur in adults and are associated with indolent behavior in this patient population.

42 if a multigene classifier is associated with indolent behavior of invasive breast cancers in women fo

43 Our results confirm the highly indolent behavior of PFL and suggest that these are char

44 mic damage led to altered tumorigenicity and indolent behavior of tumor cells in vivo.

45 ficiency and the clinical course ranges from indolent behavior to that of an aggressive malignancy.

46 ons, two large subgroups, both with a rather indolent behavior, can be distinguished: a low-grade tri

47 e most common subtype and is associated with indolent behavior, local recurrence, and insensitivity t

48 ve clinical course, whereas others having an indolent behavior.

49 espond to a subtype of the disease with more indolent behavior.

50 t' IPMNs that warrant surgical removal from 'indolent/benign' IPMNs that can be observed.

51 er has limitations related to the frequently indolent biology of the disease.

52 inhibitors stimulate metastatic outgrowth of indolent cancer cells, specifically in the bone.

53 Slow-growing or indolent cancer comprised approximately 25% of incident

54 Purpose Follicular lymphoma (FL) is an indolent cancer, with effective but rarely curative trea

55 g cancer screening detects a large number of indolent cancers that generally belong to the adenocarci

56 subsequently foster the growth of otherwise indolent carcinoma cells (responders) residing at distan

57 stronger affinities and longer half-lives in indolent cases, and weaker, short-lived contacts mediati

58 1 [dnRAG1] mice) that develop an early-onset indolent CD5(+) B-cell lymphocytosis attributed to a def

59 We found that indolent cells retained the dormant phenotype, whereas a

60 Indolent cells were found to secrete a high level of sec

61 Invasive disease includes indolent chronic rhinosinusitis, granulomatous fungal si

62 nd that a significant proportion demonstrate indolent clinical behavior, leading to increased impleme

63 -grade serous carcinomas and have relatively indolent clinical behavior.

64 subclonal mutations and is characterized by indolent clinical course and favorable outcome.

65 hich may contribute to their relatively more indolent clinical course and responsiveness to therapy.

66 ctile function is also tantamount, given the indolent clinical course of most prostate cancers, parti

67 n a MCL xenograft model, consistent with the indolent clinical course of the human SOX11-negative man

68 of these patients suggests that RALD has an indolent clinical course whereas JMML is fatal if left u

69 y affecting the head and neck area and by an indolent clinical course with an estimated 5-year surviv

70 ture B-cell neoplasm characterized by rather indolent clinical course.

71 umor, but a subset of patients may follow an indolent clinical course.

72 However, a proportion of cases may follow an indolent clinical course.

73 n response to increased perfusion and has an indolent clinical course.

74 ypes, a predominant nonnodal disease, and an indolent clinical evolution, which suggests that they ma

75 d as: 95 RS, 117 HAC, and 120 histologically indolent CLL (HIC).

76 r results establish that both aggressive and indolent CLL patients show reduced expression of miR-125

77 However, rare indolent clonal T-cell proliferations in the GI tract ha

78 is a large-vessel vasculitis with a chronic, indolent course affecting the aorta and its main branche

79 t lung cancers that manifest as NSNs have an indolent course and can be managed with annual follow-up

80 e later-onset clinical symptoms and the more indolent course in adult patients.

81 cal entity where a subset of patients has an indolent course of disease that mimics monoclonal gammop

82 L) is a chronic B-cell leukemia noted for an indolent course that ultimately results in cytopenias an

83 Though most patients have an indolent course with a life expectancy comparable to tha

84 Although the majority of SMZLs show an indolent course with a median survival of approximately

85 neous and systemic involvement, and a fairly indolent course with better response to treatment.

86 The disease often takes an indolent course, but in approximately one-third of the p

87 Although it often has an indolent course, prostate cancer remains the third-leadi

88 mors occurred only in the stomach and had an indolent course.

89 diagnosis, and small thyroid cancers have an indolent course.

90 appears to be a distinct entity with a more indolent course.

91 arely fully recover, and often experience an indolent death.

92 Overtreatment of indolent disease also results in significant morbidity.

93 Distinguishing aggressive from indolent disease and developing effective therapy for ad

94 Follicular lymphoma (FL) is an indolent disease but transforms in 2% to 3% of patients

95 Most patients are characterised by an indolent disease course and an anergic phenotype of thei

96 -grade glioma does not generally indicate an indolent disease course.

97 that SOX11 cannot be used for predicting an indolent disease course.

98 4-34/IGKV2-30 BCR Ig) display a particularly indolent disease course.

99 metastatic melanoma, which markedly turns an indolent disease into a lethal phase, is prone to preser

100 ents as well for as patients with limited or indolent disease is not defined.

101 assified at diagnosis with aggressive versus indolent disease over time.

102 Ig-unmutated CLL, where typically have more indolent disease with median survivals close to 25 years

103 emarkably heterogeneous course, ranging from indolent disease with no need for immediate therapy to r

104 During the period of indolent disease, 2HG concentration varied by less than

105 Conclusion WT-GIST is an indolent disease, and most patients survive with disease

106 eukemia (CLL) is diverse; some patients have indolent disease, never needing treatment, whereas other

107 cessary prostate biopsy and overdiagnosis of indolent disease.

108 ons on the natural history of this otherwise indolent disease.

109 ed in a prostate cancer cell line resembling indolent disease.

110 observation or less invasive approaches for indolent disease.

111 n of aggressive disease and overtreatment of indolent disease.

112 in T2 vs T1 bladder cancer and aggressive vs indolent disease.

113 nd were retrospectively defined as having an indolent disease.

114 agnosed with prostate cancer will experience indolent disease; hence, discovering genetic variants th

115 d NK-cell lymphocytosis, which are similarly indolent diseases characterized by cytopenias and autoim

116 fter excision and the MALT lymphoma remained indolent during the course of her pregnancy without radi

117 ive (My-La, HUT78, HH, MAC2A, and MAC2B) and indolent (FE-PD and MAC1) CTCL cell lines.

118 ne FL model confirm their pathogenic role in indolent FL.

119 yzing genomic data from two large cohorts of indolent FLs, we identify a pattern of mutually exclusiv

120 However, the role of such lesions in indolent follicular lymphoma (FL) is unclear and individ

121 essive Burkitt lymphoma was more likely than indolent follicular lymphoma to express matriptase alone

122 or the association of 13q deletions with the indolent form of CLL that involves microRNAs, TP53, and

123 candidate diagnostic markers to distinguish indolent from aggressive disease.

124 his scenario in follicular lymphoma (FL), an indolent GC-derived malignancy.

125 tic maturation in CLL was associated with an indolent gene expression pattern and increasingly favora

126 ts with metastatic renal-cell carcinoma show indolent growth of metastases.

127 slow-growing (between 400 and 599 days), or indolent (>/=600 days).

128 In summary, frequent RB pathway lesions in indolent, high-risk FLs indicate an untapped therapeutic

129 e, baseline platelet counts over 25 000/muL, indolent histology, and related donors were associated w

130 Thus, indolent human glioma cells deficient for TF remain viab

131 rst, locoregional tumor behavior may be more indolent in older patients for some disease sites but mo

132 n progression of lung adenocarcinoma from an indolent in situ state to a frank invasive carcinoma.

133 Prostate cancers remain indolent in the majority of individuals but behave aggre

134 ought to be due to chronic inflammation from indolent infections, leading to malignant transformation

135 Tumor lesion is characterized as chronic indolent inflammation in which the effector function of

136 Though prostate cancer is often indolent, it is nonetheless a leading cause of cancer de

137 opical corticosteroids in the therapy of any indolent keratitis.

138 We propose the term indolent lesion of epithelial origin, or IDLE, for those

139 t potential are common, and screening brings indolent lesions and their precursors to clinical attent

140 re DCIS were included as a representation of indolent lesions with limited invasive capacity.

141 ationale for this change in approach is that indolent lesions with low malignant potential are common

142 or a chimeric cDNA leads to the formation of indolent liver tumors in mice that closely resemble huma

143 ral history of prostate cancer spans from an indolent localized process to biochemical relapse after

144 bine is another purine analog widely used in indolent lymphoid cancers, often in combination with rit

145 The treatment of transformed indolent lymphoma (TRIL) often includes salvage chemothe

146 ollicular lymphoma (FL) is the most frequent indolent lymphoma and is characterized by the accumulati

147 is the more effective radiation schedule for indolent lymphoma and should be regarded as the standard

148 f hematopoietic stem cell transplantation in indolent lymphoma has been defined by the adoption of th

149 essive lymphoma is found in a LN biopsy with indolent lymphoma in a BM biopsy.

150 sease and/or the screening and monitoring of indolent lymphoma in individual patients.

151 re lacking, and it is uncertain whether this indolent lymphoma is defined by age or may occur in adul

152 FL as a biologically and clinically distinct indolent lymphoma of children and adults characterized b

153 total of 175 patients with relapsed CD20(+) indolent lymphoma requiring therapy and with previous re

154 ns between slope and risk were strongest for indolent lymphoma subtypes.

155 e in this association between aggressive and indolent lymphoma subtypes.

156 In two patients MC had evolved into an indolent lymphoma with monoclonal B-cell lymphocytosis.

157 iffuse large-B-cell lymphoma, no evidence of indolent lymphoma, and were previously untreated.

158 hallenges in the management of patients with indolent lymphoma, the difficulties starting with the di

159 ence of the transformation of the underlying indolent lymphoma.

160 y of obinutuzumab with rituximab in relapsed indolent lymphoma.

161 after induction and safety in patients with indolent lymphoma.

162 Chronic leukemias and indolent lymphomas can be well controlled for years in m

163 h relapsed follicular, mantle cell, or other indolent lymphomas such as marginal zone lymphoma.

164 ith diffuse large B-cell lymphoma, four with indolent lymphomas) had evidence of clinical activity, a

165 ffuse large B-cell lymphoma (DLBCL), two had indolent lymphomas, and four had chronic lymphocytic leu

166 sing activity as a monotherapy in refractory indolent lymphomas.

167 py induces a high LDR rate in HCV-associated indolent lymphomas.

168 ty in 68 adult patients with M (36 [53%] had indolent M and 32 [47%] had advanced M) treated by 2-CdA

169 me toxicity in various M subtypes, mostly in indolent M, refractory to multiple symptomatic therapies

170 t and are limited in clinical application to indolent malignancies of low- to intermediate-risk.

171 Follicular lymphoma (FL) is an indolent malignancy of germinal center B cells.

172 In 16 of 22 patients, a diagnosis of indolent mastocytosis could be established, and 1 patien

173 As expected, indolent MCL had less frequent B symptoms and extensive

174 We conclude that most indolent MCLs are SOX11(+) and that SOX11 cannot be used

175 flammatory myofibroblastic tumors (IMTs) are indolent mesenchymal neoplasms associated with a small r

176 er ammonium and glutamate than patients with indolent monoclonal gammopathies.

177 types of renal cancer, including tumors with indolent, multifocal presentation and solitary tumors wi

178 Essential thrombocythemia (ET) is an indolent myeloproliferative neoplasm that may be complic

179 n was limited to certain subtypes, mostly of indolent nature.

180 Follicular lymphoma (FL), an indolent neoplasm caused by a t(14;18) chromosomal trans

181 ncreatic neuroendocrine tumors (GEPNETs) are indolent neoplasms presenting unpredictable and unusual

182 neuroendocrine tumors (NF-PanNETs) are often indolent neoplasms without lymph node (LN) metastasis at

183 nifest itself in multiple ways, ranging from indolent nephropathy and inflammation to proteinuria wit

184 % of DCIS lesions are benign and will remain indolent, never progressing to invasive cancers.

185 pective clinical trials of allogeneic HCT in indolent NHL are marked by substantial variation in elig

186 e B-cell lymphoma and relapsed or refractory indolent NHL into indication-specific cohorts.

187 Indolent NHL is highly susceptible to immunologic graft-

188 ssed the optimal timing of allogeneic HCT in indolent NHL nor prospectively compared different transp

189 fuse large B-cell lymphoma, seven of 15 with indolent NHL, and two with mantle-cell lymphoma) and sev

190 s have been reported with allogeneic HCT for indolent NHL, both early and late in the disease course.

191 ferentially expressed between aggressive and indolent NHL.

192 pretreated, relapsed, or refractory CD20(+) indolent NHL.

193 ferentially expressed between aggressive and indolent NHL; 11 of 14 were validated in an independent

194 the expansion phase (n = 179), patients with indolent non-Hodgkin lymphoma (iNHL), chronic lymphocyti

195 a phase I study in 64 patients with relapsed indolent non-Hodgkin lymphoma (iNHL).

196 l transplantation (HCT) can potentially cure indolent non-Hodgkin lymphoma (NHL).

197 t relevant data regarding transplantation in indolent non-Hodgkin lymphoma and highlights the issues

198 Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma in the Western hemisphere.

199 ith histologically documented, CD20-positive indolent non-Hodgkin lymphoma refractory to rituximab we

200 l dynamic randomisation scheme stratified by indolent non-Hodgkin lymphoma subtype, rituximab-refract

201 Patients with indolent non-Hodgkin lymphoma who fail to achieve adequa

202 herapy in rituximab-refractory patients with indolent non-Hodgkin lymphoma, with manageable toxicity,

203 lar lymphoma (FL) is the most common form of indolent non-Hodgkin lymphoma, yet it remains only parti

204 nt, is effective as monotherapy for relapsed indolent non-Hodgkin lymphoma.

205 b in patients with untreated, advanced stage indolent non-Hodgkin lymphoma.

206 d and highly active as initial treatment for indolent non-Hodgkin lymphoma.

207 ptable safety profile in relapsed/refractory indolent non-Hodgkin lymphoma.

208 tibody, in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

209 ial for patients with relapsed CD37-positive indolent non-Hodgkin lymphoma.

210 ation trial for patients with relapsed CD37+ indolent non-Hodgkin lymphoma.

211 lar lymphoma (FL) is the most common form of indolent non-Hodgkin lymphoma.

212 Standard treatments for indolent non-Hodgkin lymphomas are often toxic, and most

213 ade in the overall survival of patients with indolent non-Hodgkin lymphomas, these lymphomas remain l

214 Subtypes of indolent non-Hodgkin's lymphoma included follicular lymp

215 e [R-CVP]) for treatment-naive patients with indolent non-Hodgkin's lymphoma or mantle cell lymphoma.

216 n acceptable safety profile in patients with indolent non-Hodgkin's lymphoma who had received extensi

217 e rates were observed across all subtypes of indolent non-Hodgkin's lymphoma, though the numbers were

218 open-label, phase 2 study, 125 patients with indolent non-Hodgkin's lymphomas who had not had a respo

219 activity in patients with previously treated indolent non-Hodgkin's lymphomas.

220 Indolent non-progressive forms of ductal carcinoma in si

221 NET fostered the progression of the indolent NPM1-driven myeloproliferation toward an exacer

222 how a higher tendency to recur from the more indolent ones.

223 s arise from various tissues and they may be indolent or aggressive, as is the case with skin basal c

224 mbrane gels, malignant epithelium either was indolent or grew collectively, without protrusions.

225 e to the therapeutic effect in patients with indolent or Hodgkin's lymphoma.

226 sive non-Hodgkin lymphoma (n=83), and 37% in indolent or mantle-cell lymphoma (n=65).

227 lantation, was 3.1 year and in patients with indolent or nonindolent disease, 5.9 and 2.8 years, resp

228 , we enrolled adults (aged 18-75 years) with indolent or smouldering systemic mastocytosis, according

229 nt for the treatment of severely symptomatic indolent or smouldering systemic mastocytosis.

230 cur earlier as compared to clear grafts, and indolent organisms like Moraxella are prevalent in patie

231 Some are indolent; others quickly progress to glioblastoma.

232 mutant cell subpopulation, compared with the indolent parental line, and MET attenuation decreased th

233 ght distinguish aggressive lesions from more indolent pathology.

234 PC) are suboptimal, causing overtreatment of indolent PC and risk of delayed treatment of aggressive

235 l decision-making and avoid overtreatment of indolent PC and undertreatment of aggressive disease are

236 conclusion, CLL can evolve gradually during indolent phases, and undergo rapid changes following the

237 unoglobulin light chain amyloidosis a small, indolent plasma cell clone synthesizes light chains that

238 After decades of indolent progression, such plaques may suddenly cause li

239 Overdiagnosis and overtreatment of indolent prostate cancer (PCA) is a serious health issue

240 ncing produces the opposite result in a more indolent prostate cancer cell line.

241 ts on the outgrowth of distant and otherwise indolent prostate cancer cells.

242 Many men with indolent prostate cancer often opt for radical prostatec

243 ased use of radiotherapy among patients with indolent prostate cancer with limited to no correlation

244 cancer and differentiating aggressive versus indolent prostate cancers.

245 nstraining progression might be activated in indolent Pten-null mouse prostate tumours and that inact

246 dimethyl transferase WHSC1 critically drives indolent PTEN-null tumors to become metastatic PCa.

247 however, some patients appear to have a more indolent, skin-limited disease.

248 subgroups: cutaneous mastocytosis (0.042%), indolent SM (0.285%), smoldering SM (5.991%), aggressive

249 analyzed 39 KIT D816V mutated patients with indolent SM (n = 10), smoldering SM (n = 2), SM with ass

250 l cycle-related genes, whereas patients with indolent SM displayed increased expression of adhesion-r

251 c approach to the diagnosis and treatment of indolent SM using a case-based approach of representativ

252 eoplastic MCs in 3 of 25 patients (12%) with indolent SM, 4 of 7 patients (57%) with aggressive SM, a

253 In contrast to indolent SM, in which symptoms are usually managed by no

254 ell leukemia, 19/22) whereas only 3/12 (25%) indolent SM/smoldering SM patients carried one additiona

255 ginal zone lymphoma (NMZL) is a rare form of indolent small B-cell lymphoma which has only been clear

256 omatic MM, and was negative in patients with indolent smoldering MM and monoclonal gammopathy of unkn

257 eparate clinical entities, ranging from very indolent (subset 4) to aggressive disease (subsets 1 and

258 Follicular lymphoma, the most common indolent subtype of non-Hodgkin lymphoma, is associated

259 Up to 10% of CLL patients transform from an indolent subtype to an aggressive form of B cell lymphom

260 h frequency in type A thymomas, a relatively indolent subtype.

261 n future lymphoma patients, mainly driven by indolent subtypes.

262 Clinical manifestations of indolent systemic mastocytosis (ISM) comprise mediator-r

263 Risk indicators of indolent systemic mastocytosis (ISM) in adults with clin

264 Indolent systemic mastocytosis (ISM) is a rare disease c

265 16V mutation is present in a subset of adult indolent systemic mastocytosis (ISM) patients in associa

266 Indolent systemic mastocytosis (ISM) without skin lesion

267 teoporosis occur frequently in patients with indolent systemic mastocytosis (ISM), even before 50 yea

268 marrow biopsy in patients suspected to have indolent systemic mastocytosis (ISM).

269 Two of these individuals had indolent systemic mastocytosis (ISM).

270 Indolent systemic mastocytosis (SM) patients have a vari

271 ystemic mastocytosis is further divided into indolent systemic mastocytosis and advanced systemic mas

272 its KIT and LYN kinases that are involved in indolent systemic mastocytosis pathogenesis.

273 In the indolent systemic mastocytosis population, all mast cell

274 In patients with indolent systemic mastocytosis with a history of Hymenop

275 Indolent systemic mastocytosis, including the subvariant

276 oL impairment in patients with cutaneous and indolent systemic mastocytosis, the Mastocytosis Quality

277 63% female cohort of 164 adult patients with indolent systemic mastocytosis.

278 nnaire for adult patients with cutaneous and indolent systemic mastocytosis.

279 We report 10 cases of GI involvement by an indolent T-cell lymphoproliferative disease, including 6

280 e of Blood, Perry et al describe cases of an indolent T-cell lymphoproliferative disorder (LPD) of th

281 We propose the name "indolent T-LPD of the GI tract" for these lesions that c

282 e clinical course in these patients was more indolent than that in patients with the JAK2 V617F mutat

283 ade, genetically stable, and relatively more indolent than type II OvCAs, most of which are high-grad

284 An indolent threshold (ultralow risk) of the US Food and Dr

285 eening that results in the identification of indolent thyroid cancers, and treatment of these overdia

286 A vast range of disorders--from indolent to fast-growing lesions--are labelled as cancer

287 The transition of a subset of tumors from indolent to invasive disease is associated with a poor c

288 pectrum of illnesses that vary from the most indolent to the most aggressive malignancies.

289 sease outcome is heterogeneous, ranging from indolent to very aggressive, with early recurrence.

290 p of 7.3 years from the phase III First-Line Indolent Trial of yttrium-90 ((90)Y) -ibritumomab tiuxet

291 Better tools to identify indolent tumors are needed to avoid overtreatment.

292 which TECs confer stem cell-like activity to indolent tumors is unknown.

293 ific host factor promoting the transition of indolent tumors to an angiogenic malignant state through

294 malignancy potential ranging from virtually indolent tumors to rapidly progressing cancers.

295 owever, the precise mechanism underlying how indolent tumours with PTEN alterations acquire metastati

296 TGF-beta-dependent checkpoint for PTEN-null indolent tumours.

297 uld be used on a prostatic biopsy to predict indolent versus aggressive behavior of the cancer after

298 G3 tumors on needle biopsies that are truly indolent versus those that have the potential to progres

299 ) is a rare genodermatosis in which numerous indolent, well-differentiated basal cell carcinomas deve

300 Follicular lymphoma (FL) is an indolent, yet incurable B cell malignancy.